Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 26 citations in OpenAlex.

1. While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts.Oncotarget · 2017
   Article
2. From rapalogs to anti-aging formula.Oncotarget · 2017
   Review
3. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.Aging · 2016
   Article
4. The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.Oncotarget · 2015
   Article
5. p53, a translational regulator: contribution to its tumour-suppressor activity.Oncogene · 2015
   Review
6. Rejuvenating immunity: "anti-aging drug today" eight years later.Oncotarget · 2015
   Article
7. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Oncotarget · 2014
   Article
8. Koschei the immortal and anti-aging drugs.Cell death & disease · 2014
   Review
9. Gerosuppression in confluent cells.Aging · 2014
   Article
10. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.Oncotarget · 2014
    Article
11. AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.Oncotarget · 2014
    Article
12. Latest progress in tyrosine kinase inhibitors.Oncotarget · 2014
    Article
13. Reduced bioenergetics and toll-like receptor 1 function in human polymorphonuclear leukocytes in aging.Aging · 2014
    Article
14. mTOR pathway in colorectal cancer: an update.Oncotarget · 2014
    Review
15. Geroconversion: irreversible step to cellular senescence.Cell cycle (Georgetown, Tex.) · 2014
    Review
16. Comparison of rapamycin schedules in mice on high-fat diet.Cell cycle (Georgetown, Tex.) · 2014
    Article
17. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Cell death & disease · 2013
    Review
18. Dysregulation of the mTOR pathway in p53-deficient mice.Cancer biology & therapy · 2013
    Article
19. Selective anti-cancer agents as anti-aging drugs.Cancer biology & therapy · 2013
    Article
20. Immunosuppressants in cancer prevention and therapy.Oncoimmunology · 2013
    Review

Corrections and comments

• Comment on
  Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice.2012

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract